[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647462":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":21,"locations":31,"responsibleParty":47,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Chung Shan Medical University","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"GLP-1 RA plus SGLT2i",null,"Adults with type 2 diabetes hospitalized with pneumonia who had prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission.",{"label":13,"type":10,"description":14,"interventionNames":10},"GLP-1 RA alone","Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for a GLP-1 receptor agonist, and no prescription for an SGLT2 inhibitor, in the year before admission.",{"label":16,"type":10,"description":17,"interventionNames":10},"SGLT2i alone","Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for an SGLT2 inhibitor, and no prescription for a GLP-1 receptor agonist, in the year before admission.",{"label":19,"type":10,"description":20,"interventionNames":10},"Usual care","Adults with type 2 diabetes hospitalized with pneumonia who had a prescription for metformin, a sulfonylurea, or a DPP-4 inhibitor, and no prescription for a GLP-1 receptor agonist or an SGLT2 inhibitor, in the year before admission.",[22,28],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Pen-Hua Su, PhD","CONTACT","886-4-24739595","21707","jen@csh.org.tw",{"name":29,"role":24,"phone":25,"phoneExt":26,"email":30},"Yu-Nan Huang, PhD","yunanhuang83@gmail.com",[32],{"facility":33,"status":10,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Chung Shan Medical University Hospital","Taichung","402","Taiwan","TW",{"type":39,"coordinates":40},"Point",[41,42],120.6839,24.1469,{"lat":42,"lon":41},[45,46],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},{"name":29,"role":24,"phone":25,"phoneExt":26,"email":30},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yu-Nan Huang","Assistant Professor\u002FResearch Fellow",[52],{"name":53,"class":54},"National Science and Technology Council, Taiwan","OTHER_GOV","100647462","preadmission-glp-1-receptor-agonist-plus-sglt2-inhibitor-use-and-early-outcomes-after-pneumonia-hospitalization-in-adults-with-type-2-diabetes-100647462",false,"NCT07708610","Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes","Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes: A Target Trial Emulation","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Type 2 diabetes mellitus\n* Hospitalization with pneumonia during the study period, serving as the index admission\n* Prescription of a GLP-1 receptor agonist, an SGLT2 inhibitor, or usual-care glucose-lowering therapy in the year before the index admission\n* No GLP-1 receptor agonist or SGLT2 inhibitor prescription in the 6 months before the first qualifying prescription\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus, or other specified diabetes types that are not type 2 diabetes\n* Human immunodeficiency virus infection\n* Bariatric surgery\n* Solid-organ transplantation\n* Pneumonia hospitalization, invasive mechanical ventilation, or renal replacement therapy in the year before the index admission\n* End-stage kidney disease, dialysis dependence, ventilator dependence, or tracheostomy status\n* Metastatic malignancy, lung cancer, or palliative care\n* Viral pneumonia, influenza with pneumonia, or COVID-19 around the index admission\n* Acute cardiovascular event in the 6 months before the index admission","ALL","18 Years",{"count":65,"type":66},71775,"ESTIMATED","OBSERVATIONAL","This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare preadmission glucose-lowering treatment strategies in adults with type 2 diabetes hospitalized with pneumonia. Time zero is the date of the index pneumonia admission. The study compares patients with evidence of prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission with patients prescribed a GLP-1 receptor agonist alone, an SGLT2 inhibitor alone, or usual care. Usual care includes metformin, sulfonylureas, or DPP-4 inhibitors without either study class. The primary outcome is a composite of all-cause death, invasive mechanical ventilation, or renal replacement therapy within 30 days of admission, with the individual components and 12-month mortality, major adverse cardiovascular events, and major adverse kidney events also evaluated. Propensity-score methods are used to reduce bias from nonrandom treatment selection.",[70,71],"Pneumonia","Type 2 Diabetes Mellitus (T2DM)","NOT_YET_RECRUITING","2026-07-13",{"date":75,"type":76},"2026-07-16","ACTUAL",{"date":78,"type":66},"2026-07-31",{"date":80,"type":66},"2026-08-31",{"name":5,"class":6},1]